In vivo, anti-VSIG4 treatment inhibited tumor growth in a syngeneic mouse model either as a monotherapy or in combination with anti-PD-1 accompanied by macrophage repolarization and subsequent T cell activation. The gene discussed is VSIG4; the disease is neoplasm.